🇺🇸 FDA
Patent

US 8158659

Dual-acting imidazole antihypertensive agents

granted A61KA61K31/415A61K31/4164

Quick answer

US patent 8158659 (Dual-acting imidazole antihypertensive agents) held by Theravance, Inc. expires Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Apr 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61K, A61K31/415, A61K31/4164, A61K31/417, A61K31/4188